Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70

Rhea-AI Filing Summary

Lexeo Therapeutics director Brenda Cooperstone received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to her continuous service, leaving her with 35,000 derivative securities following this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider COOPERSTONE BRENDA

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 options Exercise price: $4.70 per share Underlying shares: 35,000 shares +2 more

5 metrics

Option grant size 35,000 options Stock Option (right to buy) awarded to director

Exercise price $4.70 per share Conversion or exercise price of stock options

Underlying shares 35,000 shares Common Stock underlying the options

Expiration date June 24, 2036 Option expiration date

Holdings after grant 35,000 derivative securities Total options held following transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, grant, award, or other acquisition, +1 more

5 terms

Stock Option (right to buy) financial

"Security title is reported as Stock Option (right to buy)."

exercise price financial

"The conversion or exercise price of the option is $4.7000."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option has an expiration date of 2036-06-24."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"Transaction code A is described as Grant, award, or other acquisition."

continuous service financial

"Vesting is subject to the Reporting Person's continuous service on such date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:44 PM Accepted by SEC EDGAR 06/29/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COOPERSTONE BRENDA

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.7	06/25/2026		A		35,000		(1)	06/24/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Lexeo Therapeutics (LXEO) disclose about Brenda Cooperstone in this Form 4?

Lexeo Therapeutics reported that director Brenda Cooperstone received a grant of stock options for 35,000 shares of common stock. These options were awarded as compensation, not bought in the open market, and are classified as a derivative security award.

How many Lexeo Therapeutics (LXEO) options did Brenda Cooperstone receive?

Brenda Cooperstone received stock options covering 35,000 shares of Lexeo Therapeutics common stock. This entire amount represents a new derivative award, and her total derivative holdings following the transaction are also 35,000 option-linked shares.

What is the exercise price of Brenda Cooperstone’s Lexeo Therapeutics (LXEO) options?

The stock options granted to Brenda Cooperstone have an exercise price of $4.70 per share. This means she can purchase Lexeo Therapeutics common shares at $4.70 once the options vest and become exercisable, subject to the plan’s terms.

When do Brenda Cooperstone’s Lexeo Therapeutics (LXEO) options vest?

All of the options vest 100% on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on Brenda Cooperstone’s continuous service with Lexeo Therapeutics through the applicable vesting date.

When do Brenda Cooperstone’s Lexeo Therapeutics (LXEO) options expire?

Brenda Cooperstone’s stock options expire on June 24, 2036. After that expiration date, any unexercised options will lapse, and she will no longer be able to purchase Lexeo Therapeutics common shares under this specific award.

Was Brenda Cooperstone’s Lexeo Therapeutics (LXEO) Form 4 a market purchase or sale?

The Form 4 shows a grant or award acquisition of options, not a market trade. The transaction code is "A," indicating a compensatory grant of stock options rather than an open-market purchase or sale of Lexeo Therapeutics shares.